

TALVEY®

Patient Card



Carry this card with you at all times.

SHOW THIS CARD to any healthcare professional involved in your care and if you go to the hospital

TALVEY can cause side effects such as Cytokine Release Syndrome (CRS) and neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).¹

PATIENT'S NAME:

Important Safety Information for Patients

Get medical help straight away if you experience any of the following:

Cytokine Release Syndrome (CRS)	Neurologic toxicity, including ICANS
<ul style="list-style-type: none">• Fever• Low blood pressure• Chills• Difficulty breathing• Fatigue• Headache• Fast heartbeat• Increased level of liver enzymes in the blood	<ul style="list-style-type: none">• Feeling confused• Feeling less alert and sleepy• Feeling disorientated• Altered, slow or difficulty thinking• Decreased consciousness• Difficulty speaking, understanding speech and writing• Muscle weakness, slow movements, difficulty walking• Seizures• Memory impairment

IMPORTANT TO REMEMBER: Stay close to the location where you received your TALVEY therapy for at least 2 days for daily monitoring after administration of all doses of the step-up dosing schedule. If you have any of the symptoms listed on this card, call your doctor, or seek emergency medical attention right away! These are not all the possible side effects of TALVEY. Tell your doctor if you have any side effect that bothers you or does not go away.

Treating Physician

Treating Physician's
Name:

Treating Physician's
Phone Number:

Hospital Name
and Address:

Phone Number:

Information for Healthcare Team to Fill In

Please give this card to your healthcare team to fill in the information and return to you.

Dates of TALVEY injections (step-up dosing schedule):

STEP-UP DOSE 1

STEP-UP DOSE 2

STEP-UP DOSE 3

STEP-UP DOSE 4*

TREATMENT PHASE‡

*For the biweekly dosing only.

‡For the weekly dosing this is: 0.4 mg/kg once every week thereafter.

For the biweekly dosing this is: 0.8 mg/kg once every two weeks thereafter.

Important Safety Information for Healthcare Professionals

CRS and neurologic toxicity, including ICANS, may occur in patients receiving TALVEY, and can be fatal or life-threatening. The majority of these events observed following TALVEY administration were Grade 1 and 2.¹

Assess the patient for signs and symptoms of CRS and ICANS. If your patient reports any signs or symptoms as referenced on this card, please contact the patient's treating physician immediately for further information.

See Prescribing Information for full details.

Reporting Side Effects

This format and its contents have been reviewed and approved by the Ministry of Health in 01/12/2024.

For more information, see the patient package insert.

You can report side effects to the Ministry of Health using the online form for reporting side effects on the Ministry of Health homepage:

www.health.gov.il, or by clicking on the link:

<https://sideeffects.health.gov.il/>

Furthermore, you can report side effects directly to Johnson & Johnson Israel, by calling: 09-9591111.

¹: Talvey-2mg_ml_40mg_ml_solution for injection_PI_09_2024